Document:

<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                 EXHIBIT 10.13

                             DISTRIBUTION AGREEMENT

This Distribution Agreement (the "Agreement") is entered into this 2nd day of
May 1997, by and between Gen-Probe Incorporated, a Delaware corporation, with
its principal place of business located at 9880 Campus Point Drive, San Diego,
California 92121, USA ("GEN-PROBE"), and bioMerieux S.A., a French corporation,
having its principal place of business located at Chemin de l'Orme, 69280 Marcy
L'Etoile, France ("BIOMERIEUX").

                                    RECITALS

     A.   GEN-PROBE is a U.S. company engaged in the business of developing and
marketing various in vitro diagnostic products which utilize DNA probe
technology and products ancillary thereto;

     B.   BIOMERIEUX is a French company engaged in the business of
manufacturing and marketing various in vitro diagnostic products;

     C.   GEN-PROBE and bioMerieux Vitek, Inc., a subsidiary of BIOMERIEUX
("BMX"), have entered into certain Collaboration Agreements (as hereinafter
defined) contemplating the joint development by the parties of certain
diagnostic products utilizing their respective proprietary technologies;

     D.   In connection therewith, GEN-PROBE desires that BIOMERIEUX act as its
exclusive distributor for the sale  of certain products in certain specified
countries and BIOMERIEUX desires to act in that capacity.

                                   AGREEMENT

     Now, therefore, the parties hereto agree as follows:

     1.   Definitions. For the purpose of this Agreement, the terms set forth
below shall have the following meanings. Capitalized terms not otherwise
defined herein shall have the meanings ascribed to them in the Collaboration
Agreements.

          1.1  "Affiliate" shall mean any corporation or other business entity
which controls, is controlled by or is under common control with GEN-PROBE or
BIOMERIEUX, as applicable. For purposes of this Section 1.1, control shall mean
direct or indirect ownership of more than 50% of the voting interest or income
interest in a corporation or entity, or such other relationship as, in fact,
constitutes actual control.

          1.2  "Collaboration Agreements" shall mean the VIDAS License,
Development and Cooperation Agreement and the ANAIS License, Development and
Cooperation Agreement entered into between GEN-PROBE and BMX of even date
herewith, pursuant to which the parties to such agreements agree to collaborate
in research, development and marketing of certain products.

          1.3  "Distributorship Arrangements Agreement" means the
Distributorship Arrangements Agreement of even date herewith between the
parties.
<PAGE>
          1.4  "New Products" shall mean new in vitro diagnostic products
(other than products developed under the Collaboration Agreements) not
presently marketed by GEN-PROBE but which GEN-PROBE may during the Term in its
sole discretion determine to develop, manufacture and market and which may in
GEN-PROBE's sole discretion be added to Exhibit A upon 90 days written notice
to BIOMERIEUX, subject to receipt of all appropriate regulatory approvals to
market (such approvals to be obtained at BIOMERIEUX's expense), unless within
such 90-day period BIOMERIEUX gives notice to GEN-PROBE and, if GEN-PROBE so
requests, reasonably demonstrates in timely fashion thereafter that inclusion
of such  new in vitro diagnostic product would have a material adverse effect
on BIOMERIEUX's business as a whole. In the event BIOMERIEUX does demonstrate
such a material adverse effect, then the new in vitro diagnostic product shall
not be a "New Product" and GEN-PROBE may terminate the exclusivity of the
distribution rights granted in Section 2.1 to the extent GEN-PROBE reasonably
determines necessary in order to enable it to secure appropriate distribution of
such new in vitro diagnostic product, it being acknowledged by the parties that
any such new distributor may require the ability to sell other products as well
as the new product which BIOMERIEUX is not willing to distribute.

          1.5  "Products" shall mean the in vitro diagnostic products identified
on Exhibit A attached hereto, including the instruments described in Part I to
Exhibit A ("Instruments"), (ii) the disposables described in Part II of Exhibit
A ("Disposables"), (iii) the New Products and (iv) any and all parts and
components necessary for repair or replacement for any of the foregoing, in each
case, as the same may be modified and improved by GEN-PROBE from time to time.

          1.6  "Sale Prices" shall mean the prices of the Products payable by
BIOMERIEUX to GEN-PROBE identified on Exhibit A attached hereto, and as
established in writing from time to time by GEN-PROBE for New Products, as such
prices may be changed from time to time by GEN-PROBE pursuant to the provisions
of Section 4 hereof.

          1.7  "Term" shall mean the term of this Agreement, consisting of the
period from the date hereof until termination of this Agreement in accordance
with Section 14 hereof.

          1.8  "Territory" shall mean the territory as determined from time to
time pursuant to the Distributorship Arrangements Agreement. The parties shall
maintain a separate schedule, which they shall amend from time to time,
reflecting the countries included within the "Territory".

     2.   Appointment of Distributor.

          2.1  Engagement. GEN-PROBE hereby appoints BIOMERIEUX to act during
the Term as its exclusive distributor of Products within the Territory, as the
Territory shall be constituted from time to time, and BIOMERIEUX hereby accepts
such appointment. In addition, provided that any and all necessary consents are
obtained, GEN-PROBE will cause Gen-Probe France S.A., its French subsidiary
("Gen-Probe France"), to assign to BIOMERIEUX the contract between Gen-Probe
France and Euralam dated June 14, 1996 and BIOMERIEUX agrees to accept such
assignment, all as provided in the Distribution Arrangements Agreement.
BIOMERIEUX shall assume and discharge Gen-Probe France's duties and obligations
under such agreement. Prices charged by GEN-PROBE for goods supplied to
BIOMERIEUX for distribution to Euralam shall be at the prices indicated on
Exhibit B.

          2.2  Duties of BIOMERIEUX.

                                      -2-
<PAGE>
               2.2.1     BIOMERIEUX shall at its own cost and expense
distribute, sell, lease, market, promote, service, support and maintain the
Products in the Territory. BIOMERIEUX shall arrange the terms of sale,
including price of the Products, between itself and its customers.

               2.2.2     BIOMERIEUX shall refrain outside the Territory from
seeking customers, from establishing any branch or from maintaining any
distribution depot relating to the Products.

          2.3  NON-COMPETITION. As the sole and exclusive distributor of the
Products in the Territory, BIOMERIEUX will devote diligent efforts on a
commercially reasonable basis to marketing and promoting the Products in the
Territory, and to this end will not, either on its own behalf, or on behalf of
any other person or Affiliate, directly or indirectly, during the Term for any
reason (i) manufacture, sell, distribute or promote any products which might
materially compete with or adversely affect the sale of the Products but
excluding any standard components which might be included in the Products (it
being agreed that BIOMERIEUX  and its Affiliates may continue to manufacture
and market those products which it or they manufacture or market as of the date
hereof and any other products developed pursuant to the Collaboration
Agreements) or (ii) without the consent of GEN-PROBE, which shall not be
unreasonably withheld, employ any person who has been an employee of GEN-PROBE
or any Affiliate thereof during the year prior to the date on which such
employee is employed by BIOMERIEUX  or its Affiliate. BIOMERIEUX acknowledges
and agrees that the restraints and undertakings contained in this Section 2.3
are fair and reasonable. The foregoing prohibition as to employment shall not
apply to employees of Gen-Probe France.

     3.   PURCHASING/ORDERING PROCEDURES.

          3.1  PURCHASES; INVENTORY. BIOMERIEUX agrees during the Term to
purchase from GEN-PROBE, and GEN-PROBE agrees during the Term to use diligent
efforts on a commercially reasonable basis to supply BIOMERIEUX with, such
quantities of the Products as are necessary to maintain its inventory of the
Products (including spare parts and accessories) in a sufficient quantity to
supply customer demand for the Products within the Territory and to otherwise
effectuate the purposes of this Agreement.

          3.2  ORDERS. BIOMERIEUX will purchase the Products by submitting
written purchase orders to GEN-PROBE containing valid purchase order numbers
and signed by an authorized representative of BIOMERIEUX. GEN-PROBE will
acknowledge all accepted purchase orders from BIOMERIEUX in writing. Such
acknowledgement will verify pricing information and specify estimated time of
delivery. BIOMERIEUX shall use its reasonable efforts to place orders for the
Products in an even and regular fashion to faciliate efficient scheduling by
GEN-PROBE of its production and GEN-PROBE shall use reasonable efforts to accept
such orders in such fashion.

          3.3  MINIMUM PURCHASE COMMITMENTS. In consideration of the rights
granted to it under this Agreement, BIOMERIEUX agrees (i) to use diligent
efforts on a commercially reasonable basis to promote and support the sale and
distribution of all Products in the Territory (including by making reasonable
investments in facilities, personnel, equipment and materials) and (ii) to
purchase and accept delivery of minimum quantities of the Products for resale
in Phase I Countries during each "Performance Period" in the manner specified
on Exhibit D (the "Minimum Purchase Commitment").

               In determining whether BIOMERIEUX has satisfied the Minimum
Purchase Commitment for any given Performance Period, each such Performance
Period shall be treated on a separate

                                      -3-

<PAGE>
basis for each period. Any purchases which exceed the Minimum Purchase
Commitment in any Performance Period may not be applied to offset any
deficiencies in the Minimum Purchase Commitment for the prior or subsequent
Performance Period, as applicable. Only those purchase orders (i) placed by
BIOMERIEUX with GEN-PROBE during any given Performance Period and for which
delivery and payment therefor has been made within such Performance Period and
(ii) placed within the last ten (10) days of the previous Performance Period but
for which payment therefor has been made within the current Performance Period,
excluding purchase orders which were included in determining the Minimum
Purchase Commitment for the preceding Performance Period, or any cure period
applicable thereto, shall be included in determining whether the Minimum
Purchase Commitment therefor has been met.

               In the event that BIOMERIEUX fails to achieve the Minimum
Purchase Commitment for either Performance Period as set forth in Exhibit C,
BIOMERIEUX shall have thirty (30) days in which to cure said failure to satisfy
the Minimum Purchase Commitment through payment to GEN-PROBE of an amount equal
to sixty percent (60%) of the deficiency in the Minimum Purchase Commitment. If
BIOMERIEUX fails so to cure such failure, GEN-PROBE may, at its option and in
its sole discretion, at any time within thirty (30) days after the expiration of
the applicable cure period, (i) terminate this agreement or (ii) terminate the
exclusivity of the distribution rights granted pursuant to Section 2.1, in which
latter event, BIOMERIEUX shall be relieved of any minimum purchase commitment
under this Section 3.3 for such Performance Period and the subsequent
Performance Period, as applicable. GEN-PROBE shall exercise its rights set forth
in clauses (i) and (ii) above in each case by giving notice to BIOMERIEUX within
the aforesaid thirty (30) day period.

          3.4  FORECASTS. BIOMERIEUX shall submit to GEN-PROBE, within thirty
(30) days after the end of each calendar quarter during the Term, a written
report of sales activity during the previous quarter, broken down by country.
BIOMERIEUX shall also provide on a semi-annual basis a description of all
marketing activities undertaken by BIOMERIEUX by country in the Territory during
the previous half year, together with additional relevant information which may
include advice as to the market potential for the Products in each country,
sales trends, changes in competitive environment, regulatory climate and such
other similar matters as may be within its knowledge. BIOMERIEUX shall submit to
GEN-PROBE within thirty (30) days after the end of each calendar quarter a
summary forecast of its anticipated orders for the Products for the next
succeeding calendar quarter, and GEN-PROBE shall not be obligated to supply
quantities of Products in excess of such forecasts for any calendar quarter.
Such forecast shall be provided on a "best efforts" basis and shall not
constitute a binding commitment of BIOMERIEUX.

     4.   PRICING AND PAYMENT TERMS.

          4.1  PRICING. The price payable by BIOMERIEUX for each Product sold
hereunder shall be the Sale Price for such Product in effect on the date on
which BIOMERIEUX submits its purchase order for such Product. The Sale Prices
initially in effect are as set forth on Exhibit A. All prices are stated in U.S.
dollars F.O.B. GEN-PROBE's current U.S. point of shipment and do not include
freight, insurance or sales tax, use tax, excise tax, VAT, export and import
duties, imposts or any similar tax or assessments of any governmental entity,
all of which shall be borne solely by BIOMERIEUX (other than taxes on the net
income of GEN-PROBE). If a resale certificate or other certificate or document
of exemption is required in order to exempt the transactions described in this
Agreement from sales, value-added or use tax liability, BIOMERIEUX or GEN-PROBE,
as applicable, shall furnish to the other party with such certificate or
document prior to shipment.

                                      -4-
<PAGE>
          4.2  Pricing Changes. For orders submitted from the date hereof until
the end of the second Performance Period, Sale Prices for Phase I Countries (as
defined in the Distributorship Arrangements Agreement) shall be in effect as set
forth on Exhibit A, subject only to such increases of which GEN-PROBE shall
provide BIOMERIEUX with ninety (90) days' prior written notice. In the event
that the weighted average increase in the Sale Prices of all Products sold to
BIOMERIEUX by GEN-PROBE during any Performance Period [***], where such weighted
average is calculated [***]. GEN-PROBE may at any time and for any reason change
any Sale Price applicable for sales of Products destined for any countries of
the Territory other than Phase I Countries and for any sales of Products
destined for Phase I Countries after the end of the Second Performance Period,
provided that GEN-PROBE notifies BIOMERIEUX in writing of such change not less
than ninety (90) days prior to the effective date of such change.

          4.3  List Prices. BIOMERIEUX shall have the right to set list prices
to end users. GEN-PROBE agrees not to set, publish and/or distribute or supply
any other suggested end user prices of Products intended for sale in the
Territory.

          4.4  Payment Terms. Invoices shall be rendered for each delivery.
BIOMERIEUX shall pay GEN-PROBE in U.S. dollars for the Products and for any
other amounts for which BIOMERIEUX is liable hereunder within ninety (90) days
of invoice date or within thirty (30) days of delivery date, whichever is
later, by wire transfer to GEN-PROBE's bank account as specified by GEN-PROBE.
Any late payments shall bear interest at an annual rate of two percentage
points above the prime rate from time to time quoted by Bank of America at its
principal office in San Francisco, California, with changes in such prime rate
to be effective as of the date of each such change. Failure to make payment
when due shall constitute a breach hereof subject to applicable provisions as
to notice, cure and termination, as provided in Section 14.3(i).

     5.   Delivery, Risk and Title.

          5.1  Shipment. All shipments are F.O.B. GEN-PROBE's principal
shipping facility in the United States. GEN-PROBE shall use reasonable efforts
to provide Products to BIOMERIEUX so as to maximize their shelf life. In no
case shall any Products having a projected shelf life of less than six months
after the anticipated delivery date be presented for shipment except after
consultation and with the prior written agreement of BIOMERIEUX; provided,
however, that Amp C.T., M.T.D. and M.T.C. shall not have a projected shelf life
of less than four months. BIOMERIEUX shall specify the method of shipment and
insurance and GEN-PROBE shall attempt, in good faith, to comply with such
specification. If no such specification is made or if the specification cannot
be reasonably complied with, GEN-PROBE may select the manner of shipment and
insurance on behalf of BIOMERIEUX, but such carrier shall not be deemed to be
an agent of GEN-PROBE, nor shall GEN-PROBE have any liability for the
performance of the carrier or any delays or damage in shipment. All shipping,
transportation, insurance and similar charges shall be the responsibility of
BIOMERIEUX and, if paid or incurred by GEN-PROBE, shall be promptly reimbursed
by BIOMERIEUX to GEN-PROBE.

          5.2  Delivery Scheduling. Unless otherwise agreed in writing, during
the Term, GEN-PROBE will use its reasonable commercial efforts to deliver
Products ordered pursuant to Section 3.2 on the date specified in the
applicable order. Failing delivery on such date, and subject to BIOMERIEUX's
right of cancellation or rejection in the event of undue delay, GEN-PROBE shall
cause delivery as soon

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
                                      -5-
<PAGE>
thereafter as practicable, provided such order is made in accordance with the
terms of this Agreement and, provided, further, that GEN-PROBE reserves the
right to limit, delay or refuse shipment if BIOMERIEUX is past due on any
payment or is otherwise in breach of this Agreement. In addition, GEN-PROBE may
be excused from delivery of Products under this Agreement to the extent that
Section 16 hereof is applicable.

          5.3  Title and Risk. Title to the Products and risk of loss for the
Products shall pass to BIOMERIEUX upon the delivery to the F.O.B point as
provided in the purchase order consistent with the terms hereof. BIOMERIEUX
hereby grants to GEN-PROBE a security interest (and such similar rights under
the laws of any country) in all Products delivered hereunder and the proceeds
thereof until the purchase price therefor has been paid in full; provided,
however, that GEN-PROBE hereby releases such security interest, except in the
event that BIOMERIEUX shall be in breach as regards to payment of the purchase
price, effective upon such payment in full, and, provided further, that such
arrangements shall in no way prejudice BIOMERIEUX's right to sell the Products.
BIOMERIEUX shall execute any instruments or documents which GEN-PROBE
reasonably deems appropriate to establish and perfect said security interest
and, in any event, a copy of this Agreement may be filed at any time after
execution by BIOMERIEUX as a financing statement for that purpose; provided,
however, that such documents and instruments shall provide for such release as
contemplated above.

     6.   Packaging and Trademarks.

          6.1  GEN-PROBE Packaging. GEN-PROBE shall be responsible for
packaging the Products in its standard format with English language labelling.

          6.2  BIOMERIEUX Labelling and Packaging. Labelling on the Products
themselves and all related product literature and packaging shall state in
English that the Products are manufactured by GEN-PROBE. BIOMERIEUX shall
provide and bear the cost of additional labelling, packaging and/or product
literature (including translations) necessary or appropriate to comply with the
laws, regulations, industry and medical standards and good commercial practices
within the Territory. GEN-PROBE shall assist BIOMERIEUX, without charge, for
reasonable assistance of GEN-PROBE personnel not involving any out-of-pocket
expense and not unduly interfering with such personnel's normal business
activities, and otherwise at the expense of BIOMERIEUX, in the preparation of
such filings as may be required under laws and regulations throughout the
Territory to effectuate and maintain registration and other regulatory approvals
of Products in the Territory. BIOMERIEUX will distribute Products only with the
appropriate labelling, packaging and product literature (in every case complete
and unobscured) and only under GEN-PROBE's applicable trademarks and trade
names. GEN-PROBE shall have the right to review final labelling, packaging and
product literature and any changes thereto and no such labelling, packaging and
product literature or changes thereto shall be distributed by BIOMERIEUX without
GEN-PROBE's prior written approval.

          6.3  Trademark License. GEN-PROBE hereby grants to BIOMERIEUX the
royalty-free, non-exclusive, non-assignable (except as set forth in Section 13)
and non-sublicensable right to use GEN-PROBE's trademarks and trade names in
connection with the promotion of the Products during the Term, it being
expressly understood that BIOMERIEUX shall use GEN-PROBE's trademarks and trade
names during the Term for the sole purpose of distributing the Products
hereunder and shall promptly discontinue any and all use of such trademarks or
trade names upon the termination or expiration of the Term. BIOMERIEUX disclaims
any right to the trademarks and trade names of GEN-PROBE other than pursuant to
this license. Notwithstanding the foregoing, BIOMERIEUX may use trademarks
and trade names of GEN-PROBE only as approved by GEN-PROBE in writing (which
approval shall not be

                                      -6-
<PAGE>
unreasonably withheld). To the extent that BIOMERIEUX uses any trademark or
trade name of GEN-PROBE under this Agreement, BIOMERIEUX shall accompany any
such use with a conspicuous notation to the effect that such trademark or trade
name is owned by "Gen-Probe Incorporated" and with any other proprietary legend
which GEN-PROBE reasonably determines is necessary to protect its proprietary
interest therein. BIOMERIEUX shall not affix any trademark or trade name of
GEN-PROBE to any product other than the Products.

          6.4  Protection of Patents, Trademarks and Copyrights.  BIOMERIEUX
recognizes GEN-PROBE's right, title and interest in its patents, trademarks,
trade names and copyrights, trade secrets, and proprietary information in
connection with the Products, and BIOMERIEUX shall not claim any ownership right
thereto inconsistent with this Agreement. In the event any third party shall
infringe on GEN-PROBE's rights in its patents, trademarks, trade names or
copyrights, trade secrets or proprietary rights, BIOMERIEUX shall inform
GEN-PROBE thereof as soon as possible and, at GEN-PROBE's request, render
reasonable assistance to GEN-PROBE in prosecuting such claims.

          6.5  Authorized Distributor.  BIOMERIEUX may identify itself during
the Term as an authorized distributor of GEN-PROBE products, but shall not use
any of GEN-PROBE's trademarks or trade names in its corporate name or in any
other manner not expressly authorized by GEN-PROBE.

     7.   Technical Information and Know-How.

          7.1  Customer Support.  BIOMERIEUX shall be responsible for all
technical support as provided to current BIOMERIEUX customers and after-sales
service of its customers for the Products and shall provide such support and
service at reasonable levels acceptable to GEN-PROBE. As part of its efforts in
this regard, BIOMERIEUX shall, at its own cost and expense:

               (i) Organize, train and maintain an after sales department
consisting of a team of technicians specializing in technical maintenance,
repair and service of the Products sufficient in size to provide adequate
support to customers within the Territory; and

               (ii) Keep a record of all customer complaints, circumstances,
occurrences or conditions which have affected or could affect Product quality,
including shipment duration, storage, handling and packaging, and any other
problems, irregularities or malfunctions, including, without limitation,
technical or scientific problems which may affect the reliability of the
Products and/or the biological results obtained by customers. BIOMERIEUX shall
communicate promptly to GEN-PROBE all such matters.

          7.2  GEN-PROBE Support.  During the Term, GEN-PROBE shall provide
second-level technical customer support for the Products directly to BIOMERIEUX
at the expense of GEN-PROBE, and shall provide technical updates to BIOMERIEUX
from time to time as and if such updates become available.

          7.3  Additional Training.  At reasonable times, BIOMERIEUX, at its
expense, may send to GEN-PROBE's facility additional representatives for
training relating to the Products including theory and applications of the
Products, "hands-on" use of the Products and analysis of competitors and
competitive products.

     8.   Marketing.

                                      -7-
<PAGE>
          8.1  Diligent Efforts.  During the Term, BIOMERIEUX shall use diligent
efforts on a commercially reasonable basis to continuously promote and sell the
Products in the Territory. All costs and expenses of advertising, sales
promotion, workshops, seminars and convention exhibits shall be the
responsibility of BIOMERIEUX. BIOMERIEUX shall provide to GEN-PROBE for
GEN-PROBE's prior review and approval (which shall not be unreasonably withheld)
all English language translations of promotional materials which BIOMERIEUX
proposes to use with respect to the Products. During the Term, GEN-PROBE will
supply, at no cost to BIOMERIEUX, one set of camera ready artwork and/or color
separated negatives of advertising and promotional material used by GEN-PROBE.

          8.2  Changes in Printed Material.  During the Term, GEN-PROBE shall
notify BIOMERIEUX regarding any changes to any promotional material and/or
packaging warnings and/or instructions to accompany the Products and
BIOMERIEUX's labelling, packaging and product literature shall thereupon be
appropriately modified to conform therewith. Such notification shall be made
sufficiently in advance so as not to disrupt BIOMERIEUX's operations except in
any cases in which prompt action is required based on safety or efficacy
concerns.

          8.3  Inquiries from Outside Territory.  BIOMERIEUX shall direct to
GEN-PROBE any customer/end-user inquiries and leads received in the Territory
for delivery or use of Products outside the Territory. GEN-PROBE may use such
leads and lists without restriction for its own marketing purposes, whether or
not related to the Products or this Agreement.

     9.   Warranties, Liability and Disclaimers.

          9.1  Product Warranties.  GEN-PROBE MAKES NO REPRESENTATION OR
WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY
WARRANTY AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, EXCEPT THAT
GEN-PROBE SHALL HAVE GOOD TITLE TO THE PRODUCTS SOLD TO BIOMERIEUX HEREUNDER,
FREE OF LIENS OR OTHER CLAIMS OF OTHERS, AND EXCEPT THAT THE PRODUCTS SOLD TO
BIOMERIEUX HEREUNDER SHALL MEET THE STANDARD TECHNICAL SPECIFICATIONS THEREOF
SET FORTH IN GEN-PROBE'S PRINTED PRODUCT LITERATURE; PROVIDED, HOWEVER, THAT
WITH RESPECT TO ANY PRODUCT SOLD BY BIOMERIEUX IN THE TERRITORY, GEN-PROBE SHALL
MAKE AVAILABLE TO BIOMERIEUX AND TO THE END-USER A WARRANTY NO LESS FAVORABLE
THAN ANY WARRANTY GEN-PROBE MAY BE ISSUING AT SUCH TIME WITH RESPECT TO SUCH
PRODUCT OUTSIDE THE TERRITORY. THE FOREGOING LIMITED WARRANTY MAY BE EXPANDED
ONLY TO THE EXTENT THAT GEN-PROBE SHALL LATER ISSUE A SEPARATE SPECIFIC WRITTEN
WARRANTY TO BIOMERIEUX.

          9.2  Limitation of Remedy.  No claim based upon any alleged breach of
warranty shall be valid unless: (a) GEN-PROBE shall have received notice of such
claim in writing (i) within ninety (90) days after receipt by BIOMERIEUX of
notice of the alleged defect from a customer giving rise to such claim, or (ii)
within three years after the date of receipt by BIOMERIEUX of the Product at
issue, whichever is earlier; and (b) BIOMERIEUX shall cooperate with GEN-PROBE
in the investigation of any such claim and shall use commercially reasonable
efforts to endeavor to gain the cooperation of the affected end-users.
GEN-PROBE's warranty obligation hereunder shall be limited to the terms of any
applicable warranty made by GEN-PROBE hereunder or the replacement or repair of
defective shipments of Products, as applicable. Defective shipments of Products
(or components) will be returned to GEN-PROBE at GEN-PROBE's expense, and
Products or components replacing the defective shipments will be sent to

                                      -8-
<PAGE>
BIOMERIEUX at GEN-PROBE's expense. The foregoing warranties shall not apply to,
and GEN-PROBE shall have no liability hereunder for, any defect or failure to
the extent caused by (i) improper use, installation, repair, alteration,
mishandling or misprocessing either by BIOMERIEUX, its Affiliates, their
customers or end-users or (ii) hazards or accidents which are neither
attributable to GEN-PROBE nor to events prior to shipment of the Products by
GEN-PROBE; or (iii) negligence of BIOMERIEUX, its Affiliates or their customers
or end-users.

     9.3  Limitation of Liability.  It is hereby expressly covenanted and
agreed upon by the parties that the foregoing warranties, remedies and
undertakings are given for the benefit of BIOMERIEUX and its Affiliates and may
not be passed on except as expressly provided above, and that they are
exclusive and are in lieu of any warranties of merchantability, warranties of
fitness for a particular purpose or warranties or remedies of any other kind,
express or implied. In no event shall GEN-PROBE be liable to BIOMERIEUX or its
Affiliates for any lost revenues or profits or other special, indirect,
incidental or consequential damages, arising out of this Agreement or the
transactions contained herein, whether based in contract, tort, breach of
express or implied warranty, including, without limitation, negligence or
product liability. Subject to the remaining provisions of this Section 9,
GEN-PROBE's liability to BIOMERIEUX and its Affiliates for damages for any
cause whatsoever and regardless of the form of action (in contract or tort)
shall be limited to the purchase price stated in the particular purchase order
for the Products that caused the damages or that are the subject matter of the
cause of action, and any other amount provided for under this Section 9 and
applicable indemnification provisions herein. BIOMERIEUX shall not make any
express warranty on behalf of GEN-PROBE with regard to the Products other than
as many be from time to time provided by GEN-PROBE through any standard
warranty as set forth in GEN-PROBE's end-user product literature, as the same
may be translated for local use by BIOMERIEUX with the prior written approval
of GEN-PROBE. Except as provided above, no warranty made by BIOMERIEUX to its
customers with respect to the Products shall obligate GEN-PROBE in any way.

     9.4  Recall.  In the event that GEN-PROBE decides to recall, replace or
take other action with respect to any Products, it will immediately notify
BIOMERIEUX and BIOMERIEUX shall thereupon promptly cease sales of any units of
Products in its possession or control which are subject to the action until the
course of action to be taken has been determined. The reasonable and
justifiable costs of immediately recovering Product in the field and its
replacement, in any action affecting a Product, will be borne by GEN-PROBE.

     9.5  Product Modification.  Alterations to any Product which GEN-PROBE
deems necessary or desirable may be made by GEN-PROBE on ninety (90) days'
prior written notice to BIOMERIEUX. In the event of such change in
specifications or designs, GEN-PROBE shall be under no obligation to make such
change on any of the Products previously shipped to BIOMERIEUX provided that
such Products remain reasonably safe and efficacious for their intended use.
BIOMERIEUX shall not make any alterations or modifications whatsoever to
Products, without the express prior written consent of GEN-PROBE.

     9.6  Laws, Regulations and Ethical Standards.  BIOMERIEUX shall be
responsible for compliance with all laws and regulations affecting the sale,
handling and distribution of the Products in the Territory. BIOMERIEUX and
GEN-PROBE shall each conduct and maintain its business in material compliance
with all applicable laws, ordinances, regulations and rules of and all
governmental authorities and regulatory bodies. BIOMERIEUX and GEN-PROBE shall
not engage in any unfair trade practice, including, without limitation, (i)
false or misleading representations concerning the Products, (ii) illegal "loss
leader", "bait and switch" or other misleading or deceptive advertising or
(iii) any practice designed

                                     - 9 -
<PAGE>
improperly to control prices. Each party shall promptly notify the other in
writing of any such conduct by a representative of such party or any other
distributor or dealer, or of any complaint received by such party alleging any
such conduct.

     10.  Confidential Information

          10.1  Each party agrees to use all Confidential Information (as
hereinafter defined) of the order provided to it or obtained by it pursuant to
this Agreement. "Confidential Information" of a party shall mean any and all
confidential technical data, knowledge or information, trade secrets or advice
relating to the design, development, manufacture, assembly, use, sale,
installation or operation and servicing of its product, including modifications
thereof, whether patented or unpatented, and any and all information concerning
the finances and business of such party. Each party acknowledges the other
party's sole rights in the Confidential Information of such other party. Each
party shall ensure that, without the prior written approval of the other, no
Confidential Information of the other is used for any purpose other than as set
forth herein or disclosed to any third party (except its duly authorized
representatives, employees and agents who need to know such information
in furtherance of this Agreement) during the Term and for four (4) years after
the end of the Term. Within thirty (30) days of the end of the Term, each party
shall either return to the other party or, at the request of the other party,
destroy all Confidential Information of the other party in its possession,
including, without limitation, all manuals covering products and any customer
or prospect lists provided by the other party.

          10.2  Confidential Information shall not include:

               (i)    Information which at the time of disclosure is published
or otherwise generally available to the public through no fault of the party
to which it is disclosed;

               (ii)   Information which was in the possession of a party at the
time of disclosure to such party and which was not acquired directly or
indirectly from the other party or another party under an obligation of secrecy
to party;

               (iii)  Information rightfully acquired without restriction by a
party from a third party who did not obtain it under obligation of secrecy to
another person or entity; or

               (iv)   Information independently developed by a party prior to
the date of this Agreement without reference to information received from the
other parties, as evidenced by such parties' written records.

     11.  Infringement.

          11.1  If BIOMERIEUX receives a claim of a third party that any
Product infringes a patent, copyright or trademark or misappropriates any other
right of a third party in the Territory, then BIOMERIEUX will notify GEN-PROBE
promptly in writing within fifteen (15) days of receipt by it of such claim and
give GEN-PROBE all reasonable information, assistance and cooperation for the
defense of same at GEN-PROBE's expense. GEN-PROBE shall have the exclusive
authority to evaluate, defend and settle such claim. GEN-PROBE, at its own
expense and option, may (i) assume control of the settlement and/or defense of
such claim, (ii) allow BIOMERIEUX to do so at GEN-PROBE's expense, (iii)
procure for BIOMERIEUX the right to continue using and transferring the Product
in question, (iv) replace or modify

                                     - 10 -
<PAGE>
the Product so that no infringement will occur or (v) remove the Product
involved from Exhibit A and refund the price thereof as depreciated or
amortized over the lifetime of the Product as established by GEN-PROBE.
Provided BIOMERIEUX has given GEN-PROBE reasonable notice, assistance and
cooperation, GEN-PROBE will pay any damages or settlement finally awarded on
account of such claim; provided GEN-PROBE, in the case of settlement, approves
such settlement.

          11.2      Notwithstanding the foregoing, GEN-PROBE shall not be
liable to BIOMERIEUX to the extent any such claim is based upon (i) use of the
Products in connection with or combination with any other products, equipment,
devices or software not provided or delivered by GEN-PROBE and where such use
or combination was not otherwise approved by GEN-PROBE, (ii) modification
(otherwise than as directed or approved by GEN-PROBE pursuant to Section 9.5 or
Section 11.3 hereof) of or damage to the Products after shipment by GEN-PROBE,
(iii) any use of the Products in a manner different from that specified in
GEN-PROBE's product literature or (iv) any negligent acts of BIOMERIEUX. Unless
otherwise permitted by GEN-PROBE, BIOMERIEUX shall promptly suspend sale and
distribution of any Product after receipt of an infringement claim (and the
parties shall in good faith consult as to the possible adjustment of any
applicable Minimum Purchase Commitment, if any). GEN-PROBE's obligations
hereunder shall not apply to any infringement claim asserted after BIOMERIEUX
has received notice alleging the infringement unless GEN-PROBE has given
BIOMERIEUX express written permission for such continuing distribution
notwithstanding the allegation of infringement.

          11.3      Notwithstanding any other provisions hereof, GEN-PROBE
shall not be liable for any claim based on BIOMERIEUX's use of the Products as
shipped after GEN-PROBE has informed BIOMERIEUX of modifications or changes in
the Products or their use required to avoid such claims and offered to
implement those modifications or changes, if such claim would have been avoided
by implementation of GEN-PROBE's modifications or changes.

          11.4      The provisions of this Section 11 are solely for
BIOMERIEUX's and its Affiliates' benefit and shall be in lieu of, and GEN-PROBE
expressly disclaims, any warranties of noninfringement with respect to the
Products.

          11.5      BIOMERIEUX shall indemnify GEN-PROBE for, and hold it
harmless from, any loss, cost or expense suffered or incurred in connection
with any claim, suit, or proceeding brought against GEN-PROBE, insofar as it is
based on the modification or alteration of a Product other than by GEN-PROBE or
as directed or approved by GEN-PROBE pursuant to Section 9.5 or Section 11.3 or
the combination of a Product with any equipment, device, or software not
supplied by GEN-PROBE where such combination was not approved by GEN-PROBE.

     12.  Relationship of the Parties. BIOMERIEUX acknowledges that both
parties hereto are independent contractors and that no partnership shall be
deemed to be formed under this Agreement. BIOMERIEUX shall, on its own behalf,
solicit orders for Products only as an independent contractor. BIOMERIEUX shall
arrange the terms and conditions of sale of Products, including price,
independent of GEN-PROBE. BIOMERIEUX shall not represent itself as a partner,
joint venturer, agent, employee or general representative of GEN-PROBE. Except
as specifically provided herein, BIOMERIEUX acknowledges that it shall have no
right, power or authority to in any way obligate GEN-PROBE to any contract or
other obligation.

     13.  Non-Assignment. Neither party to this Agreement shall have the right
to assign, delegate, mortgage, pledge, hypothecate, sublicense or otherwise
transfer any rights or obligations under this

                                      -11-

<PAGE>
Agreement without the written consent of the other party, which shall not be
unreasonably withheld. Any such purported transfer without such consent shall
be deemed void and without effect. For purposes of this Agreement, "assignment"
shall include (i) the transfer of substantially all of the assets of a party,
even if this Agreement is specifically excluded from such transfer and (ii) any
change in the ultimate beneficial control of a party. Notwithstanding the
foregoing, either party may assign and transfer this Agreement, including all
its rights and obligations hereunder, to any Affiliate of such party, provided,
that such assignment shall not relieve the assigning party of its obligations
hereunder. In addition, either party may assign and transfer this Agreement,
including all its rights and obligations hereunder, to any party succeeding to
substantially all its business, and GEN-PROBE may assign or transfer any rights
to receive payments hereunder upon reasonable prior notice to BIOMERIEUX.
Notwithstanding the foregoing, on thirty (30) days' prior written notice to
GEN-PROBE, BIOMERIEUX may appoint subdistributors with respect to any
particular country or countries, provided that no such appointment shall
relieve BIOMERIEUX of any obligations hereunder.

     14.  Termination.

          14.1      The term of this Agreement (the "Term") shall be three
years from the date first above written, unless earlier terminated hereunder.
Not less than one year prior to the scheduled expiration of the Term, the
parties shall commence good faith negotiations regarding a possible extension
of the Term on mutually acceptable terms, provided that, unless the parties
shall have reached mutual agreement on the terms and conditions of such an
extension within six (6) months of the scheduled expiration of the Term, the
Term shall automatically expire on the date set forth in the first sentence of
this Section 14.1.

          14.2      Notwithstanding the foregoing, GEN-PROBE may at its option
terminate this Agreement in accordance with the terms of Section 3.3 if
BIOMERIEUX fails to meet the Minimum Purchase Commitments in any Performance
Period of the Term.

          14.3      This Agreement and/or the exclusivity of the
distributorship thereof may be terminated by either party prior to the scheduled
expiration of the Term on written notice given to the other party in the event
of:

                    (i)       A material breach of any terms (including any
payment terms) of this Agreement or the Distributorship Arrangements Agreement
by the other party not cured within sixty (60) days (thirty (30) days for any
obligation to pay monies unless the same is disputed in good faith, in which
case, to avert default, the paying party may deposit the disputed amount with a
third-party escrow agent pending resolution of such dispute and interest shall
be payable on all disputed amounts determined to be payable at an annual rate of
two percentage points above the prime rate from time to time quoted by Bank of
America at its principal office in San Francisco, California, with changes in
such prime rate to be effective as of the date of each such change) from and
after written notice of such breach is given by the terminating party;

                    (ii)      The liquidation or insolvency of or the filing of
bankruptcy or similar proceedings with respect to the other party (provided that
in the case of involuntary proceedings, such proceedings are not dismissed
within sixty (60) days after filing);

                    (iii)     The other party ceasing to be actively engaged in
business; or

                                      -12-

<PAGE>
               (iv)  The other party engaging in or being charged with unethical
or illegal practices thereby jeopardizing, in the reasonable opinion of the
terminating party, its reputation and good will.

          14.4 Upon termination or expiration of this Agreement:

               (i)   BIOMERIEUX shall submit to GEN-PROBE within thirty (30)
days after the effective date of any expiration or termination of the Term a
list of all Products in BIOMERIEUX's inventory as of the effective date of the
termination. If GEN-PROBE terminates this Agreement pursuant to Section 14.2 or
14.3, GEN-PROBE may, in its sole discretion, repurchase any or all Instruments,
Products and spare parts in the inventory of BIOMERIEUX or installed in the
Territory at the time of termination at the price paid by BIOMERIEUX for said
Products and spare parts, except that, in the case of Instruments, such price
shall be reduced to the reacquisition price as determined in accordance with
Exhibit C to the Distributorship Arrangements Agreement. If BIOMERIEUX
terminates this Agreement pursuant to Section 14.3, BIOMERIEUX shall have the
right to cause GEN-PROBE to effect the repurchases described in the preceding
sentence at the prices described in such sentence. Upon any expiration of this
Agreement, GEN-PROBE will use reasonable efforts to obtain a commitment by the
successor distributor appointed by it to repurchase such Instruments and
Inventory on the basis set forth in Exhibit C to the Distributorship
Arrangements Agreement.

               (ii)   In the event of termination of this Agreement by GEN-PROBE
pursuant to Section 14.3, GEN-PROBE may, at its option, cancel all or part of
any scheduled but unshipped deliveries.

               (iii)  All rights of BIOMERIEUX to sell and distribute Products
hereunder shall be terminated except that BIOMERIEUX may continue to distribute
in accordance with normal business practice and subject to the terms of this
Agreement (and subject to GEN-PROBE's rights under Section 14.4.(i)) Products
previously shipped to it by GEN-PROBE for a period of no more than six (6)
months following such termination or expiration.

               (iv)   BIOMERIEUX shall transfer to GEN-PROBE any and all Product
registrations, including, without limitation, ADM registrations secured by
BIOMERIEUX. GEN-PROBE agrees to reimburse BIOMERIEUX for the reasonable costs
of transferring such registrations.

               (v)    BIOMERIEUX shall provide to GEN-PROBE a list of all
current customers of the Products.

               (vi)   GEN-PROBE and BIOMERIEUX shall each have the right to
terminate the Distributorship Arrangements Agreements effective at the time of
termination of this Agreement.

          14.5 Continuing Obligations. Except as otherwise expressly
specifically provided herein, the expiration or termination of this Agreement
shall not release either party from any liability or obligation arising prior to
the date of such expiration or termination.

          14.6 Goodwill. Upon the expiration or termination of this Agreement,
BIOMERIEUX shall not under any circumstances be entitled to compensation or
damages of any kind, whether on account of the loss by BIOMERIEUX of present or
prospective sales, investments, compensation or goodwill. BIOMERIEUX, for itself
and on behalf of each of its employees, agents and representatives, hereby
waives any rights which may be granted to it or them under the laws and
regulations of the Territory, including,

                                      -13-
<PAGE>
without limitation, any claim for compensation or indemnification (i) for its
loss of business or goodwill, (ii) based on unjust enrichment to GEN-PROBE and
(iii) with respect to any damage incurred by it or by them as a result of
termination of its rights hereunder. BIOMERIEUX hereby agrees to indemnify and
hold GEN-PROBE harmless from and against any and all claims, costs, damages and
liabilities whatsoever asserted by any employee, agent or representative of
BIOMERIEUX under any applicable termination, labor social security or other
similar laws or regulation of the Territory.

     15.  Indemnification.

          15.1   BIOMERIEUX agrees to indemnify, defend and save harmless
GEN-PROBE and its Affiliates, and their officers, directors, agents, employees,
legal representatives, successors and assigns, and each of them, from any and
all claims, actions, suits, liabilities, judgments, losses, damages, costs,
charges, attorneys' fees (hereinafter "Losses") (whether incurred in any action
between GEN-PROBE and BIOMERIEUX or between GEN-PROBE and any third party),
caused or resulting, directly or indirectly, from any acts or omissions of
BIOMERIEUX in connection with the Products or its related business activities
(including, without limitation, any breach by BIOMERIEUX of this Agreement),
except to the extent any such Losses (i) are covered under GEN-PROBE'S warranty
and limited liability as set forth herein, (ii) result from any breach by
GEN-PROBE of its obligations hereunder or (iii) result from the fault of
GEN-PROBE. BIOMERIEUX further agrees that the provisions contained in this
section shall survive the termination or expiration of this Agreement.
BIOMERIEUX will maintain at all times during the term of this Agreement and
provide evidence to GEN-PROBE of general operating and product liability
insurance policies of a kind and in an amount reasonably satisfactory to
GEN-PROBE.

          15.2   GEN-PROBE agrees to indemnify, defend and save harmless
BIOMERIEUX and its Affiliates, and their officers, directors, agents,
employees, legal representatives, successors and assigns, and each of them,
from any and all Losses (whether incurred in an action between GEN-PROBE and
BIOMERIEUX or between BIOMERIEUX and any third party), to the extent (i) caused
or resulting, directly or indirectly, from any acts or omissions of GEN-PROBE
in connection with the Products or its business activities relating to
manufacture thereof (including, without limitation any breach by GEN-PROBE of
this Agreement) except to the extent any such Losses result from any breach by
BIOMERIEUX of its obligations hereunder or (ii) resulting from fault of
BIOMERIEUX. GEN-PROBE further agrees that the provisions contained in this
section shall survive the termination or expiration of this Agreement.
GEN-PROBE will maintain at all times during the term of this Agreement and
provide evidence to BIOMERIEUX of general operating and product liability
insurance policies of a kind and in an amount reasonably satisfactory to
BIOMERIEUX.

     16.  Force Majeure. Neither party shall be liable for any loss or damage
resulting from any delay in performing or failure to fulfill any term of this
Agreement (other than BIOMERIEUX'S obligation to make payment for Products
actually purchased and delivered) so long as such delay or failure arises from
an event of force majeure including, but not limited to, fire, flood, storm or
other acts of the elements, war, riot, act of God, strike, lockout or other
industrial dispute, any law, regulation, rule, order, proclamation or
requirement of any national state or local government having jurisdiction over
the parties or Products, plant breakdown or failure of equipment, inability to
obtain equipment fuel, power, materials or transportation, or by any
circumstances whatsoever beyond a party's reasonable control.

     17.  Notices. All notice or other communication in connection with this
Agreement must be in writing and if by mail, by certified mail, return receipt
requested, and shall be effective when delivered to

                                      -14-
<PAGE>
the addressee at the address listed below or such other address as the
addressee shall have specified in a notice actually received by the addressor.

     If to GEN-PROBE:

          Gen-Probe Incorporated
          9880 Campus Point Drive
          San Diego, California 92121
          Attention: President

     If to BIOMERIEUX

          bioMerieux S.A.
          69280 Marcy l'Etoile
          Lyon, France
          Attention: President

     18.  Export Regulations.

          18.1 BIOMERIEUX shall be responsible for and shall bear all costs of
obtaining import and export licenses and all governmental consents or
authorizations with respect to shipment of the Products into the Territory from
the United States and shall demonstrate to GEN-PROBE's satisfaction compliance
with applicable laws and regulations prior to the scheduled date for any
shipment outside the United States. BIOMERIEUX shall be responsible for and
shall bear all costs of clearing the Products through customs in the Territory
and shall pay all customs duties with respect thereto.

          18.2 Neither BIOMERIEUX nor any Affiliate thereof nor any customer
thereof, as provided in the following sentence, shall export from the country
in which it first takes possession of any Products or technical information
with respect thereto, or re-export from anywhere, any Products or technical
information with respect thereto (or a direct product thereof, including
without limitation, processes and services unless it had first complied with,
and demonstrated to Seller's reasonable satisfaction compliance with, all
applicable export regulations, including, without limitation, those of the
United States. To the extent required and/or permitted by applicable law,
BIOMERIEUX and its Affiliates will make reasonable efforts to impose a like
obligation upon their customers and shall take all reasonable steps available,
including legal action, to enforce such obligation.

     19.  Miscellaneous.

          19.1 The failure of either party to enforce its rights under this
Agreement at any time for any period shall not be construed as a waiver of such
rights.

          19.2 No changes or modifications or waivers can be made to this
Agreement unless evidenced in writing and signed for and on behalf of both
parties.

          19.3 In the event that any provision of this Agreement shall be
determined to be unenforceable, all other provisions shall remain in full force
and effect and the afflicted provision shall be construed so as to be
enforceable to the maximum extent possible.

                                      -15-
<PAGE>
          19.4 This Agreement shall be governed by and construed in accordance
with the laws of the State of New York without regard to the conflicts of laws
or provisions thereof and excluding the United Nations Convention on Contracts
for the International Sale of Goods, except that any arbitration hereunder
shall be governed by Section 19.6 below. Headings herein are for convenience of
reference only and shall in no way affect interpretation of the Agreement.

          19.5 Such terms and conditions of BIOMERIEUX's orders or other sales
documents as may be in conflict in whole or in part with the provisions of this
Agreement shall be of no force or effect whatsoever and the provisions of this
Agreement shall be controlling in any such instance. It is the intention of
both parties hereto that the acceptance, even in writing, of any such purchase
or sales document not constitute a modification or amendment of or addition to
the terms of this Agreement unless accompanied by a typed letter Agreement
conspicuously entitled "Amendment of Agreement" which begins with a proposal to
amend the Agreement and specifies exactly each change to be made and which is
signed by an authorized officer of both parties.

          19.6 In the event of any controversy or claim relating to, arising
out of or in any way connected to any provision of this Agreement ("Dispute"),
the parties shall seek to settle their differences amicably between themselves,
including entering into non-binding mediation. Any unresolved Dispute shall be
finally resolved by final and binding arbitration in accordance with this
Section 19.6. Whenever a party shall decide to institute arbitration
proceedings, it shall give written notice to that effect to the other party.
The party giving such notice shall refrain from instituting the arbitration
proceedings for a period of ten (10) days following such notice to allow the
parties to attempt to resolve the Dispute between themselves. If the parties
are still unable to resolve the dispute, the party giving notice may institute
the arbitration proceeding under the rules of Conciliation and Arbitration of
the International Chamber of Commerce as then in effect ("ICC Rules").
Arbitration shall be held in New York, New York. The arbitration shall be
conducted before three arbitrators, with each party to select one arbitrator
and with the third arbitrator to be appointed in accordance with ICC Rules. The
arbitrators shall undertake in writing as a condition of service to conduct
proceedings in a speedy and efficient manner to render the award promptly after
the final arbitration hearing, and further shall confirm in writing to the
President of the Court of Arbitration of the International Chamber of Commerce
that such undertaking is being or has been fulfilled, or shall report the
reasons for any failure of fulfillment, as a condition for any application for
fees. If so requested by either party, preparation of any Terms of Reference
referred to in ICC Rules shall be waived and the matters at issue in the
Dispute shall be determined by the arbitrators based on the timely submissions
of the parties, the arbitrators shall not have the power to award punitive
damages or any award of multiple damages under this Agreement and such awards
are expressly prohibited. Any arbitral award shall be by majority vote and
shall be final and binding on the parties. Judgment on the award may be entered
in any court having jurisdiction. Except to the extent entry of judgment and
any subsequent enforcement may require disclosure, all matters relating to the
arbitration, including the award, shall be held in confidence by the parties.
Nothing contained in this Section 19.6 shall prevent either party from seeking
temporary restraining orders, injunctions or such other relief in any court of
competent jurisdiction.

     19.7 Each of BIOMERIEUX and GEN-PROBE acknowledge that it will be
impossible to measure in money the damages that would be suffered if BIOMERIEUX
fails to comply with the obligations imposed on it pursuant to Sections 2.3 and
6.3 or if either party fails to comply with the obligations of Section 10 of
this Agreement and that in the event of any such failure, the applicable party
will be irreparably damaged and will not have an adequate remedy at law.
GEN-PROBE and BIOMERIEUX, as applicable, shall, therefore, be entitled to
injunctive relief and/or specific performance to enforce such obligations and,
if any action should be brought in equity to enforce any of said provisions

                                      -16-
<PAGE>
of this Agreement, and neither party shall raise the defense that there is an
adequate remedy at law. Notwithstanding the provisions of Section 19.6 above,
each of GEN-PROBE and BIOMERIEUX, as applicable, may enforce its rights under
Sections 2.3, 6.3 and 10 in any court having competent jurisdiction.

     19.8  In the event that this Agreement is required to be registered with
any governmental authority in the Territory. BIOMERIEUX shall cause such
registration to be made and shall bear any expense or tax payable in respect
thereof.

     19.9  The official text of this Agreement shall be in the English language,
and such English text shall be controlling in all respects, notwithstanding any
translation hereof required under the laws and regulations of the Territory. The
parties undertake to use the English language in respect of all documents and
contemplated hereby, except where another language must be used under the laws
and regulations of the Territory. In any such case, a certified English
translation shall be supplied to the other party by the party using such
documents or making such communication.

AGREED TO AND ACCEPTED BY

GEN-PROBE INCORPORATED                         BIOMERIEUX, S.A.

By: /s/ Daniel L. Kacian                       By: /s/ Philippe A. Archinard
   ----------------------------                   ----------------------------
   Name:  Daniel L. Kacian                        Name:  Philippe A. Archinard
   Title: Senior Vice President and               Title: Authorized Signatory
          Chief Scientific Officer

                                      -17-
<PAGE>
                                   Exhibit A

                            Products and Sale Prices

                                      -18-
<PAGE>
<Table>
<Caption>
                                                                           Transfer
Cat. No.                 Product Description                                 Price
<S>         <C>                                                              <C>
  1591      MTC                                                              [***]
  1791      DETECTION REAGENT                                                [***]
  1792      PACE2 CT (less 10%)                                              [***]
  1793      PACE2 NG (less 10%)                                              [***]
  3300      FEMALE COLLECTION (less 20%)                                     [***]
  3375      MALE COLLECTION (less 20%)                                       [***]
  2930      FAST EXPRESS                                                     [***]
  2325      STD PANEL                                                        [***]
  3548      PACE 2CT COMPETI                                                 [***]
  3549      PACE 2NG COMPETI                                                 [***]
  3905      PACE 2C FOR CT&NG (less 10%)                                     [***]
  2800      ACCUPROBE GENERIC REAGENT                                        [***]
  2810      ACCUPROBE CAMPYLO                                                [***]
  2815      ACCUPROBE ENTERO                                                 [***]
  2820      ACCUPROBE GROUP B                                                [***]
  2825      ACCUPROBE HAEMOPHILI                                             [***]
  2830      ACCUPROBE NG                                                     [***]
  2835      ACCUPROBE M.AVIUM                                                [***]
  2840      ACCUPROBE M.INTRACEL                                             [***]
  2845      ACCUPROBE M.AVIUM COMPLEX                                        [***]
  2850      ACCUPROBE M.CORDONE                                              [***]
  2855      ACCUPROBE M.KANSASII                                             [***]
  2880      ACCUPROBE MTS                                                    [***]
  2865      ACCUPROBE STEREPT PNEUMONIAE                                     [***]
  2875      ACCUPROBE STAPHYLO AUREUS                                        [***]
  2890      ACCUPROBE BLASTOMYCES DERMA                                      [***]
  2895      ACCUPROBE COCCIDIODES IMMITIS                                    [***]
  2910      ACCUPROBE HISTOPLASMA CAPSUL                                     [***]
  2920      ACCUPROBE LISTERIA                                               [***]
  2925      ACCUPROBE GROUP A STREPT                                         [***]
  3765      ACCUPACE GROUP A STREP I.D.                                      [***]
 1001E      MTD (less 30%)                                                   [***]

LR0030      AMP POS.CON                                                      [***]
LR0010      AMP NEG.CON                                                      [***]
  3390      GROUP A STREPT DIRECT                                            [***]
  4000      GROUP A STREPT COLLECTION                                        [***]
  1012      AMP-CT (less 20%)                                                [***]
  1015      SWAB. AMPLIFIED CT (less 20%)                                    [***]
  1018      URINE, AMPLIFIED CT (less 20%)                                   [***]
  1018      AMPLIFIED MALE COLLECTION SWAB                                   [***]
  2900      AccuLDR                                                          [***]
  3100      LEADER 50                                                        [***]
 31001      LEADER 50I                                                       [***]
 32001      LEADER 450I                                                      [***]
  2775      HEAT-BATH (20 TUBE CAPABILITY)                                   [***]
  4008      HEAT-BATH (50 TUBE CAPABILITY)                                   [***]
  1357      SONICATOR RACK(14 HOLE)                                          [***]
  4027      SONICATOR RACK (50 HOLE)                                         [***]
 2775A      HEATING BLOCK INSERT(20 TUBE CAPABILITY)                         [***]
  1714      BOTTLE TOP DISPENSER(2 ML)                                       [***]
  3078      BOTTLE TOP DISPENSER(5 ML)                                       [***]
  2113      EPPENDORF REPEAT PIPET                                           [***]
  1438      PACE MAGNETIC SEPARATION UNIT(80 TUBE)                           [***]
 1630T      PACE MAGNETIC SEPARATION TUBE RACK                               [***]
  2065      PACE REACTION TUBE(120/BOX)                                      [***]
  2085      PACE SEALING CARDS(35/PACK)                                      [***]
  1847      LEADER PRINTER PAPER                                             [***]
  3010      WASH BOTTLE & CAP ASSEMBLY                                       [***]
  4085      PLUGGED PIPETTE TIPS                                             [***]
  3984      50-WELL STRIP RACK                                               [***]
  4008      BLUE SNAP CAPS                                                   [***]
  2440      POLYPROPYLENE TUBES                                              [***]
  2168      TRITIUM STANDARD                                                 [***]
 </Table>

             1) 1995-96 Larry Kaplan report (1996-97 was not used)

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                                   Exhibit B

                              Euralam Sale Prices

[***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -19-
<PAGE>
                                   Exhibit C

     The first "Performance Period" shall mean the twelve-month period
commencing on the first day of the calendar quarter next succeeding the calendar
quarter during which the "Territory" (as defined hereunder) first includes Phase
I Countries (as such term is defined in the Distributorship Arrangements
Agreement) whose combined total of 1996 sales of Products (as specified for each
such country in the table below) equals or exceeds [***]. The second Performance
Period shall commence on the anniversary of said date.

     BIOMERIEUX agrees to purchase from GEN-PROBE (i) Products that are resold
in the Phase I Countries which have an aggregate Sale Price of at least [***]
during the First Performance Period, and (ii) Products that are resold in the
Phase I Countries which have an aggregate Sale Price of at least [***] during
the Second Performance Period. Purchases of Products that are resold in
countries not constituting Phase I Countries shall not be taken into account for
purposes of determining whether the Minimum Purchase Commitment has been
satisfied; provided, however, that in the event that any Phase I Country or
Countries are not a part of the Territory during any part of the Territory
during any part of any calendar month constituting a part of such Performance
Period, then with respect to each such missing country and each month of such
period for which it is absent, the applicable Minimum Purchase Commitment shall
be reduced by a percentage of such Minimum Purchase Commitment equal to 1/12th
of the Applicable Percentage. This "Applicable Percentage" shall be equal to the
absent country sales for 1996 divided by total Phase I Countries sales for 1996,
expressed as a percentage.

               Country                            1996 Sales Amount

               France                                     [***]
               Italy                                      [***]
               Germany                                    [***]
               Spain (Portugal)                           [***]
               Austria                                    [***]
               Switzerland                                [***]
               United Kingdom                             [***]
               Australia                                  [***]
               Benelux                                    [***]
                                                       __________

                                                          [***]
                                                       ==========

c:\nyfs02\churcpa\crpmisc\0068572.12
May 2, 1997 9:06pm

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -20-<PAGE>

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.14

                     DISTRIBUTORSHIP ARRANGEMENTS AGREEMENT

     This Distributorship Arrangements Agreement (the "Agreement") is entered
into this 2nd day of May, 1997, by and between Gen-Probe Incorporated, a
Delaware corporation, with its principal place of business located at 9880
Campus Point Drive, San Diego, California 92121, USA ("GEN-PROBE"), and
bioMerieux S.A., a French corporation, having its principal place of business
located at Chemin de l'Orme, 69280 Marcy L'Etoile, France ("BIOMERIEUX").

RECITALS

     A.   BIOMERIEUX and GEN-PROBE have entered into a Distribution Agreement
of even date herewith, pursuant to which BIOMERIEUX has agreed to act as
exclusive distributor for the sale of certain GEN-PROBE products in certain
specified countries.

     B.   To permit BIOMERIEUX to assume responsibilities as exclusive
distributor for GEN-PROBE, GEN-PROBE will undertake negotiations to terminate
its existing distribution agreements relating to such countries in an orderly
fashion consistent with all legal obligations toward existing distributors; and

     C.   BIOMERIEUX will assist GEN-PROBE in connection with such negotiated
arrangements, by providing a Termination Allocation on a country by country
basis as provided hereafter.

AGREEMENT

     Now, therefore, the parties hereto agree as follows:

          1.        Definitions. For the purposes of this Agreement, the terms

set forth below shall have the following meanings. Capitalized terms not
otherwise defined herein shall have the meanings ascribed to them in the
Distribution Agreement.

               1.1  "Phase I Countries" shall mean France, Italy, Malta,
Germany, Spain, Portugal, Austria, Switzerland, Liechtenstein, United Kingdom,
Australia, Ireland, Netherlands, Belgium and Luxembourg.

               1.2  "Phase II Countries" shall mean South Korea, New Zealand,
Greece, Singapore and Iceland.

               1.3  "Phase III Countries" shall mean any countries not listed
as Phase I Countries or Phase II Countries, but excluding the (i) United
States, Canada and Japan and (ii)

<PAGE>
the Peoples Republic of China, Hong Kong, Taiwan, Philippines, Malaysia,
Indonesia, Singapore and Thailand. It is recognized that the parties may in the
future consider the possible inclusion of one or more of the countries listed in
sub-clause (ii) of the preceding sentence within the Phase III Countries,
provided that any such inclusion shall require a written amendment of this
Agreement and, provided further, that neither party shall be under any
obligation whatsoever to agree to any such inclusion or to execute any such
amendment. If GEN-PROBE elects to appoint an exclusive distributor other than
Chugai Pharmaceuticals or an Affiliate of Chugai Pharmaceuticals in any of the
countries listed in sub-clause (ii) of the next preceding sentence, GEN-PROBE
shall give BIOMERIEUX priority consideration for such appointment.

          1.4  "Termination Allocation" shall mean (i) for each Phase I Country
and on a country-by-country basis, up to the maximum amount of [***] which
BIOMERIEUX will pay to GEN-PROBE in respect of payments made by GEN-PROBE (other
than the amounts described in Section 2.1(b) below) to terminate GEN-PROBE's
present distributors, as calculated in accordance with Exhibit A hereto, and
(ii) for Phase II Countries and Phase III Countries, the aggregate amount of
[***] to be paid in respect of the termination of existing distributors in such
other countries as the parties shall mutually agree. The total of the foregoing
sums is hereinafter referred to a the "Termination Amount".

          1.5  "Territory" shall mean such of the Phase I Countries, Phase II
Countries and Phase III Countries in which all existing distribution agreements
with third parties relating to the distribution of GEN-PROBE's Products in such
countries as have been designated by GEN-PROBE on Exhibit A have been terminated
by mutual agreement of GEN-PROBE and such third parties in such manner as to
permit BIOMERIEUX to undertake its responsibilities hereunder, it being agreed
that (i) no such country shall be deemed to be included within the Territory
unless and until all the designated distribution agreements for said country
have been so terminated, (ii) no country identified as a Phase II Country shall
be deemed to be included in the Territory unless and until all of the Phase I
Countries have become part of the Territory (except that the foregoing
requirement may be waived by BIOMERIEUX in its sole discretion in respect of any
of the Phase I Countries (although any such waiver shall not affect GEN-PROBE's
obligation to effect such terminations)), and (iii) no country identified as a
Phase III Country shall be deemed to be included in the Territory unless so
designated by mutual written agreement of the parties hereto.

     2.   Termination of Existing Arrangements.

          2.1  Third Party Distributors.

               (a) Attached hereto as Exhibit B is a list of all third party
distributors currently distributing GEN-PROBE's Products within the Phase I
Countries, the Phase II Countries and the Phase III Countries as of the date
hereof ("Existing Distributors"). GEN-PROBE agrees to use all reasonable efforts
to terminate its distribution agreements in Phase I Countries with each of said
distributors as promptly as possible, it being agreed that such efforts shall be
an ongoing requirement during a reasonable period until success is achieved in
each

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -2-

<PAGE>
such country but shall not be deemed to require aggregate payments by GEN-PROBE
to any such third parties in any country of total amounts in excess of the
Termination Allocation for such country, increased by the excess, if any, of the
amount, if any, by which the Termination Allocation for Phase I Countries as to
which all the designated distribution agreements have been previously terminated
by GEN-PROBE exceeded the amount actually paid to the terminated distributors
therein. With respect to each of the Phase I Countries, the Termination
Allocation (adjusted as aforesaid) shall be paid by BIOMERIEUX to GEN-PROBE
within five days of certification by GEN-PROBE that one or more agreements have
been reached for the termination of all the distribution agreements with respect
to such country or (in the case of the Benelux countries, the Benelux region to
be considered as a unit), subject only to the payment of termination amounts to
the Existing Distributor(s) not exceeding the amounts described above. The
Termination Allocation for the Phase II Countries and the Phase III Countries
shall be paid as the parties mutually agree.

               (b)  It is understood and agreed that GEN-PROBE may seek to
repurchase the inventory of systems and reagents and the installed base of
systems from each terminated distributor. GEN-PROBE undertakes to use
reasonable efforts to reacquire the inventory of systems and reagents and the
installed base of systems from each terminated distributor on the terms and
conditions set forth in Exhibit C. To the extent GEN-PROBE is able to effect
such repurchases in accordance with Exhibit C, BIOMERIEUX shall be obligated,
upon completion of an appropriate audit, to purchase such inventory and systems
at a price equal to the amount so paid by GEN-PROBE to the applicable
terminated distributor for the relevant items. In each case, GEN-PROBE and
BIOMERIEUX shall cooperate with each other in any reasonable arrangements
designed to minimize any sales, use, value added and other taxes applicable to
such transactions, including, by way of example, through the assignment by
GEN-PROBE to BIOMERIEUX of its right to purchase such inventory. GEN-PROBE
shall use best efforts to procure the transfer to BIOMERIEUX of any and all
product registrations obtained by the prior distributors.

          2.2  Transfer of French Assets and Operations.  Notwithstanding
anything to the contrary in Section 2.1, GEN-PROBE's existing arrangements in
France shall be terminated and operations transferred to BIOMERIEUX as provided
in Exhibit D hereto, which shall constitute an integral part of this Agreement.

          2.3  GEN-PROBE's Obligation of Good Faith Compliance. All termination
negotiations by GEN-PROBE with Existing Distributors throughout the Territory
shall be carried out by GEN-PROBE in good faith consistent with applicable
legal requirements. BIOMERIEUX will not be called on to participate in any such
negotiations or to pay any of the costs thereof except as otherwise provided
herein.

     3.   Termination of Exclusivity.

     In the event that BIOMERIEUX fails to achieve the Minimum Purchase
Commitment for any Performance Period and GEN-PROBE, pursuant to Section 3.3 of
the

                                      -3-

<PAGE>
Distribution Agreement, terminates the exclusivity of the distribution rights
granted pursuant to Section 2.1 thereof, GEN-PROBE shall no longer be required,
from and after the effective date of exercise of such right, to terminate any
remaining distribution agreements of Existing Distributors hereunder.

     4.   Termination of Distribution Agreement.

     This Agreement shall remain in effect until the expiration of the
Distribution Agreement. If GEN-PROBE shall terminate the Distribution Agreement
in accordance with the provisions thereof, GEN-PROBE shall have the right to
terminate this Agreement at the time of such termination. In addition, either
party may terminate this Agreement on written notice given to the other party
prior to the scheduled expiration of the Term in the event of a material breach
of any of the terms hereof or of the Distribution Agreement (including any
payment terms) by the other party not cured within sixty (60) days (thirty (30)
days for an obligation to pay monies unless the same is contested in good faith,
in which case, to avert default, the paying party may deposit the disputed
amount with a third-party escrow agent pending resolution of such dispute and
interest shall be payable on all disputed amounts determined to be payable at an
annual rate of two percentage points above the prime rate from time to time
quoted by Bank of America at its principal office in San Francisco, California,
with changes in such prime rate to be effective as of the date of such change)
from and after written notice of such breach is given by the terminating party.
Termination of this Agreement shall not release either party from any liability
or obligation arising prior to the date of such expiration or termination.

     5.   Application of Provisions.

     The provisions set forth in Section 10 (Confidential Information), Section
12 (Relationship of the Parties), Section 14 (Termination) (other than Section
14.4), Section 15 (Indemnification), Section 17 (Notices) and Section 19
(Miscellaneous) (other than Section 19.5) of the Distribution Agreement shall
apply, mutatis mutandis to this Agreement as if set forth here in full and the
"Agreement" as referred to in such Sections shall be deemed for these purposes
to be this Agreement.

AGREED TO AND ACCEPTED BY

GEN-PROBE INCORPORATED                       BIOMERIEUX, S.A.

By: /s/ Daniel L. Kacian                     By: /s/ Philippe A. Archinard
   ----------------------------------           -----------------------------
   Name:   Daniel L. Kacian                     Name:   Philippe A. Archinard
   Title:  Senior Vice President and            Title:  Authorized Signatory
           Chief Scientific Officer

                                   - 4 -
<PAGE>
                         EXHIBIT A

                    Termination Allocation
                    ----------------------

     1.   Based upon sales information provided by GEN-PROBE, the parties have
estimated that the Termination Allocation for each Phase I Country shall be as
set forth below. The parties shall reasonably consult with each other as to the
adequacy of such estimated allocations based upon actual negotiations with the
terminated distributors.

<Table>
<S>                           <C>
Australia                      [***]
Germany                        [***]
Ireland                        [***]
Italy/Malta                    [***]
Austria                        [***]
United Kingdom                 [***]
Spain/Portugal                 [***]
Switzerland/Liechtenstein      [***]
Benelux                        [***]
                              --------
                               [***]
                              ========
</TABLE>

     2.   In addition, BIOMERIEUX shall reimburse GEN-PROBE for up to [***]
of termination payments made to expedite the termination of Existing
Distributors in Phase II Countries and Phase III Countries, subject to mutual
agreement of the parties with respect to such payments. GEN-PROBE shall
reasonably consult with BIOMERIEUX concerning such terminations in the Phase II
Countries so as to afford BIOMERIEUX a reasonable opportunity to commence
distribution operations in such countries.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                              - 5 -
<PAGE>
                         EXHIBIT B

                    List of Existing Distributors

                             - 6 -
<PAGE>
                                        International Distributors

    [4 Pages of International Distributors Deleted Pursuant to Confidential
                               Treatment Request]
<PAGE>
                                   EXHIBIT C

                          Certain Terms and Conditions

     GEN-PROBE shall endeavor to acquire inventory and installed systems from
the Existing Distributors in the applicable countries on the following basis:

     A. Inventories of Reagents - on the basis of final cost paid by the
Existing Distributor for the reagents ("Landed Cost Basis"). GEN-PROBE shall
seek to acquire such inventories subject to their conformity (after audit) with
BIOMERIEUX quality standards and provided that they have a remaining shelf life
of at least six months.

     B. Inventories of Systems and System Parts - on a Landed Cost Basis.
GEN-PROBE shall seek to acquire such inventories that are in working order and
at the time of purchase appear in GEN-PROBE's latest catalogue with respect to
the territory involved (i.e., are marketable in the applicable territory).

     C. Installed Systems - on the basis set forth below for such systems
installed during the specified period,

Period from Installation to Reacquisition       Reacquisition Price/Basis
-----------------------------------------       -------------------------
          less than 1 year                      [***] Landed Cost Basis*
          from 1 to 2 years                     [***] Landed Cost Basis*
          from 2 to 3 years                     [***] Landed Cost Basis*
          more than 3 years                     [***] Landed Cost Basis*

--------------
*    But only if systems are still being used by the clients for whom they are
installed, and are still generating sales by way of reagent supply.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.
<PAGE>

                                   EXHIBIT D

                    Transfer Of French Assets and Operations
                    ----------------------------------------

I.   Transfer Of Certain Assets and Operations of Gen-Probe France, S.A.

     In connection with conclusion of the accompanying Distributorship
Arrangements Agreement between Gen-Probe Incorporated ("GEN-PROBE") and
bioMerieux S.A. ("BIOMERIEUX"), GEN-PROBE will cause its wholly owned French
subsidiary, GEN-PROBE France, S.A. ("GP France"), to make the following
assignments and transfers to BIOMERIEUX and BIOMERIEUX will accept the same.

     A.   Assignment of Agreements.

          1.   All rights and obligations of GP France under the lease agreement
               dated May 12, 1993, as amended to date, between GP France and
               Vecteur Sud S.A. GP France will use reasonable efforts to obtain
               any necessary consent of lessor or any other third party to such
               assignment and, upon such assignment, GP France will surrender
               occupancy of the demised premises to BIOMERIEUX. Rentals and
               occupancy costs shall be allocated between GP France and
               BIOMERIEUX pro rata to the respective portions of such year when
               each is in occupancy of the premises. GEN-PROBE  represents that
               rental payments under such lease are FF. 143,000 per year, with
               maintenance expense of FF. 19,100, and may be subject to normal
               commercial escalation.

          2.   All rights and obligations of GP France under the distribution
               agreement dated June 6, 1994 between Euralam, S.A. and GP France
               (the "Euralam Agreement"). In connection with such assignment,
               GEN-PROBE undertakes to supply products to BIOMERIEUX or to
               Euralam for the account of BIOMERIEUX as provided in Article IV
               below.

          3.   Such other contracts of GP France deemed necessary for its
               distribution of products of GEN-PROBE in France as the parties
               may agree.

     B.   Transfer of Employees.

          GEN-PROBE will cause GP France to use reasonable efforts to cause four
          employees selected by BIOMERIEUX to accept employment with BIOMERIEUX
          and BIOMERIEUX shall extend an offer of employment to them on terms
          and conditions substantially equivalent to those of their present
          employment. GEN-PROBE has caused the terms and conditions of their
          present employment to be disclosed to BIOMERIEUX by GP France and
          GEN-PROBE warrants the

                                     - 8 -
<PAGE>
          accuracy of such disclosure. GEN-PROBE shall use reasonable efforts to
          cause GP France to obtain any approvals and authorizations required in
          connection with such transfer.

     C.   Transfer of Inventory.

          GEN-PROBE shall cause GP France to permit BIOMERIEUX to inspect and
          audit its inventory and to transfer its inventory to BIOMERIEUX in
          accordance with the terms and conditions set forth in Exhibit C to the
          Distributorship Arrangements Agreement and on the basis therein
          provided, and BIOMERIEUX shall make payment accordingly. On
          termination of the Distributorship Arrangements Agreement, GEN-PROBE
          shall have the option to repurchase any inventory acquired by
          BIOMERIEUX from GP France in accordance with Section 4 of said
          agreement.

     D.   Payment for Goodwill.

          BIOMERIEUX shall pay to GP France, simultaneously with the transfers
          referred to above, the sum of [***] in respect of value of custom and
          good will in connection with the foregoing arrangements and transfers.

II.  GEN-PROBE Retention of Ownership of GP France.

     GEN-PROBE shall retain ownership of the shares of GP France. GP France
shall remain responsible for all contracts, agreements, liabilities,
obligations, debts and other encumbrances of GP France, of whatever nature, not
specifically transferred or assigned to BIOMERIEUX as provided above (the
"Retained Obligations") and GEN-PROBE shall indemnify and hold BIOMERIEUX
harmless in respect of such Retained Obligations. If GEN-PROBE proceeds to
cause the winding-up and dissolution of GP France, GEN-PROBE shall be
responsible for all income tax obligations and other costs in connection
therewith. Each Party shall be responsible for, and shall pay when due, all
applicable sales, value added or similar taxes payable by it in connection with
the transfers contemplated by this Exhibit D.

III. Non-Competition.

     Inasmuch as GEN-PROBE  is appointing BIOMERIEUX as its exclusive
distributor pursuant to the Distribution Agreement concluded between GEN-PROBE
and BIOMERIEUX of even date herewith, GEN-PROBE shall not cause or permit any
distribution of products, goods or services through GP France in such manner as
to violate such agreement.

IV.  Supply of Products as Needed for Sale to Euralam.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -9-
<PAGE>

          GEN-PROBE shall supply to BIOMERIEUX its requirements of products for
fulfillment of obligations to Euralam pursuant to the Euralam Agreement. Such
supply shall be pursuant to the terms of Distribution Agreement except that (1)
prices shall be $48 per kit (Acuprobe Listeria) and (2) BIOMERIEUX and
GEN-PROBE shall accelerate orders and corresponding supply in such manner as
may be necessary to permit BIOMERIEUX to make timely supply to Euralam.

                                      -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]